Edmond DE Rothschild Holding S.A. Acquires New Shares in Baxter International Inc. $BAX

Key Points

• Edmond DE Rothschild Holding S.A. acquired 2.44 million Baxter International shares worth approximately $52.0 million, representing about 0.47% of the company. Institutional investors collectively own 90.19% of Baxter.
• Baxter reported quarterly EPS of $0.56, exceeding the $0.37 analyst consensus, while revenue rose 5.3% year over year to $2.96 billion. The company reaffirmed fiscal 2026 EPS guidance of $1.95–$2.15.
• Despite shares trading up 2.6% at $26.61, analysts maintain a consensus “Hold” rating with an average price target of $22.45. Baxter also declared a quarterly dividend of $0.01, implying a 0.2% annualized yield.

Edmond DE Rothschild Holding S.A. acquired a new position in shares of Baxter International Inc. (NYSE:BAX - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,437,052 shares of the medical instruments supplier's stock, valued at approximately $51,958,000. Edmond DE Rothschild Holding S.A. owned approximately 0.47% of Baxter International as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Basepoint Wealth LLC bought a new stake in shares of Baxter International during the fourth quarter valued at about $26,000. Imprint Wealth LLC purchased a new stake in shares of Baxter International in the third quarter worth about $27,000. MUFG Securities EMEA plc bought a new position in shares of Baxter International in the second quarter valued at approximately $46,000. Los Angeles Capital Management LLC bought a new position in shares of Baxter International in the fourth quarter valued at approximately $46,000. Finally, Versant Capital Management Inc grew its stake in Baxter International by 552.2% during the second quarter. Versant Capital Management Inc now owns 2,413 shares of the medical instruments supplier's stock valued at $51,000 after acquiring an additional 2,043 shares in the last quarter. Institutional investors own 90.19% of the company's stock.

Baxter International Trading Up 2.6%

Shares of BAX opened at $26.61 on Thursday. Baxter International Inc. has a 1-year low of $15.73 and a 1-year high of $30.00. The company has a market capitalization of $13.76 billion, a P/E ratio of -12.86, a P/E/G ratio of 3.92 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The firm's 50 day simple moving average is $23.40 and its 200 day simple moving average is $20.27.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.19. The business had revenue of $2.96 billion during the quarter, compared to analysts' expectations of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. The business's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Sell-side analysts forecast that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be given a $0.01 dividend. The ex-dividend date is Friday, August 28th. This represents a $0.04 annualized dividend and a yield of 0.2%. Baxter International's payout ratio is -1.93%.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on BAX shares. TD Cowen upped their target price on shares of Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a report on Monday, July 27th. Citigroup raised shares of Baxter International from a "sell" rating to a "neutral" rating and raised their price target for the company from $17.00 to $28.00 in a report on Friday, July 31st. Wells Fargo & Company boosted their price target on shares of Baxter International from $19.00 to $23.00 and gave the company an "equal weight" rating in a research report on Friday, July 31st. Zacks Research raised shares of Baxter International from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 11th. Finally, Stifel Nicolaus increased their price objective on Baxter International from $19.00 to $24.00 and gave the stock a "hold" rating in a research report on Tuesday, July 28th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $22.45.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source